Objectives: To determine fulvestrant efficacy and tolerability in Turkish patients with hormone receptorpositive metastatic breast cancer. Methods: Patients who developed metastasis while taking tamoxifen or aromatase inhibitors in the adjuvant period or metastatic disease at the diagnosis. Fulvestrant 500 mg was administered intramuscularly every 28 days. Progression-free survival (PFS) and overall survival (OS) durations were calculated. Results: In this particular research, totally 137 patients were participated. Median PFS was 9 months (95% CI, 5.7-10.3). The 12-month PFS rate was calculated as 42%, and the 36-month PFS rate was 17%. The median PFS was not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months in the second and subsequent lines respectively. Results indicated that this difference was statistically significant (p = 0.002). It was shown that patients with liver and brain metastasis had lower PFS compared patients with no liver and no brain metastasis. The estimated median OS was 38 months after fulvestrant started. The 12-month OS rate was calculated as 82.4%, and the 36-month OS rate was 50%. Conclusions: Fulvestrant contributes both PFS and OS in patients with hormone receptor-positive metastatic breast cancer and this effect is more clear in using fulvestrant as first-line treatment. The European Research Journal 2019 ndocrine therapy has preferred a form of treatment for hormone receptor (HR) positive early stage breast cancer and advanced stage breast cancer. Endocrine therapy agents that are not cross-resistant to sequential administration prolong the chemotherapy-free period and have limited toxicity-effective disease stabilization. Tamoxifen has been the backbone of endocrine therapy for almost the last 30-40 years. In metastatic disease, response rate increases up to approximately 30% by using tamoxifen [1] [2] [3] . Tamoxifen and its metabolites are linked to the estrogen receptor (ER) and this receptor modulation also causes the antagonistic effect as an estrogenic effect [4] . Another group of drugs used in endocrine therapy is aromatase inhibitors (AI). In randomized clinical trials, AI was superior to tamoxifen in postmenopausal women [1, 3] . Fulvestrant, a 17 beta-estradiol analog, is a selective ER antagonist that suppresses estrogen signaling E
The European Research Journal 2019 ndocrine therapy has preferred a form of treatment for hormone receptor (HR) positive early stage breast cancer and advanced stage breast cancer. Endocrine therapy agents that are not cross-resistant to sequential administration prolong the chemotherapy-free period and have limited toxicity-effective disease stabilization. Tamoxifen has been the backbone of endocrine therapy for almost the last 30-40 years. In metastatic disease, response rate increases up to approximately 30% by using tamoxifen [1] [2] [3] . Tamoxifen and its metabolites are linked to the estrogen receptor (ER) and this receptor modulation also causes the antagonistic effect as an estrogenic effect [4] . Another group of drugs used in endocrine therapy is aromatase inhibitors (AI). In randomized clinical trials, AI was superior to tamoxifen in postmenopausal women [1, 3] . Fulvestrant, a 17 beta-estradiol analog, is a selective ER antagonist that suppresses estrogen signaling by binding to ER and inducing a conformational change [5, 6] . Dimerization is subsequently blocked, triggering accelerated degradation and downregulation of the ER protein [5] . Fulvestrant exhibits lack of cross-reactivity with tamoxifen. The clinical efficacy of fulvestrant was initially demonstrated in two phases III trials that compared fulvestrant 250 mg per month with anastrozole 1 mg daily as a secondline therapy for advanced breast cancer [7, 8] . A combined analysis of these trials demonstrated that time to progression (TTP) with fulvestrant 250 mg was noninferior to anastrozole [9] . The phase III CONFIRM trial found that fulvestrant 500 mg was associated with improved progression-free survival (PFS) and overall survival (OS) compared with the 250 mg dose in patients who experienced disease recurrence or progression after previous endocrine therapy [10, 11] . The FIRST study reported that improved OS with fulvestrant 500 mg treatment compared with anastrozole in the first-line setting for ER-positive advanced breast cancer, with an approximately 30% reduction in mortality risk [12] In this retrospective study, we investigated fulvestrant efficacy and tolerability in Turkish patients with hormone receptor-positive metastatic breast cancer.
METHODS
This study was planned as a retrospective single center study. Istanbul Okmeydanı Training and Research Hospital obtained medical information from the archive files of patients who were treated with hormone receptor positive and HER 2 negative metastatic breast cancer in the medical oncology clinic. Patients who developed metastasis while taking tamoxifen or aromatase inhibitors in the adjuvant period or metastatic disease at the diagnosis. Fulvestrant 500 mg was administered intramuscularly every 28 days (500 mg loading after 14 days from the first dose). PFS and OS durations were calculated by obtaining the date of starting Fulvestrant treatment, date of progression and date of the last visit from patient files.
Statistical Analysis
SPSS 15.0 for Windows program was used for statistical analysis. Comparisons of ratios in groups were made with Chi Square Analysis. Monte Carlo simulation was applied when conditions were not met. The survival analyzes were performed with Kaplan Meier Analysis. A statistical significance level of alpha was accepted as p < 0.05.
RESULTS
In this particular research, totally 137 patients were participated . The median age was 53 (min.: 27 -max.: 91). The median follow-up time was 20 months (0-78 months). 20.9% patients were metastatic stage at the diagnosis. 22% of patients had not received any endocrine treatment before fulvestrant (Table1). During the follow-up period, 65% of the patients developed progression, 35% had no progression and still continued to use Fulvestant. Median PFS was 9 (95% CI 5.7-10.3) months ( Figure 1 ). The 12-month PFS rate was calculated as 42%, and the 36-month PFS rate was 17% ( Table 2 ). The median PFS was not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months in the second and subsequent lines respectively. Results indicated that this difference was statistically significant (p = 0.002) ( Table-3 ). There was no significant difference in PFS according to age, hormone and cerb-2 status in subgroup analyzes. It was clear that patients with liver and brain metastasis had lower PFS compared patients with no liver and no brain metastasis, the median PFS in patients with liver metastasis was 6 months (no liver metastasis 11 months) and in patients with brain metastasis was 3 months (no brain metastasis 10 months) these differences were statistically significant (p = 0.004 and p = 0.011 respectively in patients liver metastasis and brain metastasis). But PFS in patients with bone or lung or lymph node metastasis not statistically significant difference compared patients with no metastasis at these sites (p = 0.235, p = 0.632 and p = 0.156 respectively) ( Table-4 ). The estimated median OS was 38 months after fulvestrant started. The 12-month OS rate was calculated as 82.4%, and the 36-month OS rate was 50%. 12-month (Table 5) . OS rate was 95% in the first line use of fulvestrant in the metastatic period but 81.8%, 82.6 %, 75.5% in the second, third and fourth line respectively. But this difference was not statistically significant (p = 0.149). Also median OS, in patients using fulvestrant as firstline, was 48 months (Table 6 ). In subgroup analyzes, there was a statistically significant OS difference in patients with liver metastasis compared with patients had no liver metastasis, the median OS was 18 months and 52 months respectively (p = 0.049). Also in patients with brain metastasis compared with patients had no brain metastasis, the median OS was significantly lower (12 months and 38 months respectively, p = 0.001) ( Table 4) . In all patients, toxic effects such as myalgia, arthralgia, fever and bone complications were observed in 23.9% of the patients and grade 3-4 toxic effect was not observed.
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DISCUSSION
This particular research was a retrospective study that had been analyzed the clinical outcomes of fulvestrant treatment in post-menopausal patients with advanced breast cancer. It is found that median PFS had been 9 months. In two studies on Japanese women with advanced breast cancer treated with fulvestrant were reported that PFS was 5.4-5.5 months [13, 14] . In another study by Ishida et al. [15] , fulvestrant in Japanese women with metastatic breast cancer that progressed after endocrine therapy was found that the median time to progression was 6.1 months.
In CONFIRM study, the median PFS was 6.5 months. In this study, fulvestrant treatment had been only located in the second line [10] . In this study there had been patients treating with fulvestrant first to the fourth line, but approximately 50% of patients were in the first line group. In this study trial, The median PFS had not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months in the second and subsequent lines respectively (p = 0.002). In the univariate analysis of this particular study found a lower PFS, regarding the presence-absence of liver and or brain metastasis. Similarly, FALCON study reported that in the presence of visceral disease PFS was significantly lower [16] . Kawaguchi et al. [13] found a similar PFS in the presence or absence of visceral disease. In contrast to the results found in this study and the FALCON study sub-analysis, a metaanalysis by Graham et al. [17] of four randomized controlled trials found that fulvestrant was associated with greater benefit in advanced breast cancer patients with visceral metastasis.
The estimated median OS was 38 months after fulvestrant started, in this particular study. The FIRST study was eveluated overall survival of patients who were postmenopausal women with estrogen receptorpositive, locally advanced/metastatic breast cancer who had no previous therapy for advanced disease received either fulvestrant 500 mg (days 0, 14, 28, and every 28 days thereafter) or anastrozole 1 mg (daily). The median OS was reported 54.1 months in the FIRST study [12] . But in the FACT trial, the median OS was 37.8 months in patients receiving fulvestrant plus anastrazole. The patients in FACT trial was received fulvestrant and anastrazole in first-line at metastatic disease but fulvestrant was used 250 mg [18] . In our trial, aproximately half of patients have used fulvestrant at second and further lines and median In the FIRST study, 70.1% of patients experienced at least one adverse effects; the incidence of serious adverse effects was 11.9% with fulvestrant [12] . In the FALCON trial, 73% of patients in the fulvestrant group reported the adverse event and serious adverse events were reported by 13%. The most common side effects were arthralgia [17] . In our retrospective study, toxic effects such as myalgia, arthralgia, fever and bone complications were observed in 23.9% of the patients and grade 3-4 toxic effect was not observed.
CONCLUSION
In conclusion, fulvestrant contributes both PFS and OS in patients with hormone receptor-positive metastatic breast cancer and this effect is more clear in using fulvestrant as first-line treatment. 
